References
- Emberton M. The hallmarks of BPH progression and risk factors. Eur Urol Suppl 2003;2:2–7.
- Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Arch Intern Med 1995;155:477–81.
- Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year rando-mized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996;155:1251–9.
- Roehrborn CG, McNicholas T. The management of pro-static obstruction: how to determine the best options? Eur Urol Suppl 2003;2:13–9.
- Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Writing Committee, the American Urological Association. Transurethral prostatectomy: immediate and postoperative complications. Cooperative study of 13 participating institu-tions evaluating 3,885 patients. J Urol 1989;141: 243–9.
- Carlin BI, Bodner DR, Spinnak JP, Resnick MI. Role of finasteride in treatment of recurrent hematuria secondary to benign prostatic hyperplasia. Prostate 1997;31:180–2.
- Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol 1995;154:1779–82.
- Sieber PR, Rommel FM, Huffnagle HW, Breslin JA, Agusta VE, Harpster LE. The treatment of gross hematuria secondary to prostatic bleeding with finasteride. J Urol 1998; 159:1232–3.
- McConnell JD, Stoner E. 5 alpha-reductase inhibitors. Adv Protein Chem 2001;56:143–80.
- Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finasteride decreases perioperative bleed-ing associated with transurethral resection of the prostate. Urology 2000;55:684–7.
- Pareek G, Shevchuk M, Armenakas A, Vasjovic L, Hochberg DA, Basillote JB, et al. The effect of finasteride on the expression of vascular endothelial growth factor and micro-vessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003;169:20–3.
- Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185–91.
- Stoner E. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group J Urol 1992;147:1298–302.
- Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002;168:2024–6.
- Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992;70 (1 Suppl):291 —301.